Alzheimer’s disease
Conditions
Interventions
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
50 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1) Age 50–90 years old; 2)Voluntary participation in this study, with informed consent signed by the patient and/or a family member; 3)With or without cognitive decline. Participants who meet any of the following criteria: AD diagnosed according to the NIA–AA 2024 criteria with Aß positive status (clinical stage 4–6) for Alzheimer's disease dementia; AD-type MCI diagnosed according to the NIA–AA 2024 criteria (clinical stage 2–3); Preclinical AD as defined by the NIA–AA 2024 criteria (clinical stage 1); Cognitively normal controls determined to be Aß negative by PET-CT; Other types of cognitive impairment or neurodegenerative diseases, including vascular cognitive impairment, Parkinson’s disease, frontotemporal dementia, Lewy body dementia, Huntington’s disease, amyotrophic lateral sclerosis, etc.
Exclusion criteria
Exclusion criteria: 1)Individuals with major neuropsychiatric disorders; 2)Individuals with severe systemic diseases, such as life-threatening dysfunction of major organs (heart, liver, kidneys), severe hematologic disorders, advanced malignant tumors, etc; 3)Individuals with allergies to tracers or contrast agents used in this study, including 11C-PiB, AV45, AV1451, MK6240, FDG, or gadolinium-based contrast agents; 4)Individuals who violate study rules, show poor compliance, or refuse to participate in this project.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood-Based Biomarkers for AD;EEG; | — |
Secondary
| Measure | Time frame |
|---|---|
| MRI;PET-CT; | — |
Countries
China
Contacts
Public ContactWang Yan-Jiang;Wang Jun
Army Medical Center of PLA
Outcome results
None listed